Myopia control is the set of treatments doctors use to slow how fast a child’s eyes grow. When a child’s prescription changes every year, it is easy to assume stronger lenses are just part of growing up. That assumption misses something important. The eye is not only producing blurry vision, it is physically growing longer. That growth raises the risk of serious problems later in life. The sections below explain how that process works, which treatments help, and how doctors choose the right approach.
Key Takeaways
- A child’s eye that keeps growing longer raises the lifetime risk of retinal detachment and myopic maculopathy.
- FDA-approved options like MiSight contact lenses, Stellest glasses, and low-dose atropine drops can slow that growth.
- Treatment decisions depend on a child’s age, prescription, and how quickly it’s changing.
- Starting treatment early helps protect a child’s vision long term.
- Find answers to the most common questions parents ask about slowing childhood nearsightedness.
Why Childhood Myopia Progression Puts Long-Term Vision at Risk
Childhood myopia progresses because the eye grows too long, not because a child simply needs a stronger prescription. That physical lengthening is what separates nearsightedness in children from nearsightedness in adults whose eyes have already stopped changing.
What Is Axial Eye Elongation and Why Does It Matter?
Axial eye elongation means the eye is growing longer from front to back. In a healthy eye, light lands precisely on the retina. When the eye grows past its correct length, light falls short of the retina, and distant objects blur.
Each year of unmanaged progression adds axial length. As that measurement increases, so does the risk of complications.
Parents often notice the pattern before doctors point it out. A child may need a new prescription every few months instead of every year or two. Glasses that felt strong months ago may no longer help. This steady pattern differs from a single prescription jump, which does not always signal ongoing eye growth.
Doctors track this pattern using more than a standard vision chart. Measuring how quickly a child’s eyes are lengthening gives a clearer picture than the prescription alone. Two children with the same prescription can carry very different levels of risk.
The Long-Term Risks of Untreated Progression
High myopia, defined as -6.00 diopters or more, raises the risk of vision-damaging conditions. Retinal detachment is one of the most serious, since a longer eye means a thinner retina that tears more easily. Myopic maculopathy is another concern, since the macula handles central vision, and eye growth can damage it.
The focusing mechanism in a child’s eye is more flexible than an adult’s. That flexibility explains why myopia tends to move quickly during school years. It also explains why treatment works, since the eye still responds to signals about how it should grow.
Children’s vision is most vulnerable between ages 6 and 14, when growth spurts drive the fastest changes. A child who is mildly nearsighted at age 8 can reach high myopia by early adolescence if nothing changes.
That outcome is not guaranteed. The American Academy of Ophthalmology notes that for children who do reach high myopia, the lifetime risk of retinal detachment is about 1 in 20. That risk is why avoiding it takes more than updating a prescription each year.
None of this means every changing prescription points to a serious problem. Most children who need updated glasses each year have straightforward, correctable myopia. The goal is simply to know which pattern a child’s eyes are following. That knowledge shapes which treatment approach makes the most sense.
Myopia Control Treatments: Lenses, Drops, and Specialized Options
These treatments target the eye’s growth directly, rather than simply compensating for the prescription a child already has. Contact lenses, specialized eyeglasses, and eye drops each work differently, and each has clinical evidence behind it.
FDA-Approved Treatment Options
The American Academy of Ophthalmology recognizes several FDA-approved categories for slowing this kind of progression in children.
Stellest glasses use a lens design that creates a specific pattern of focus across the peripheral retina. That pattern signals the eye to slow its growth. Patients wear them like standard prescription glasses, though the optical effect is different.
MiSight 1 Day and Brilliant Futures MiSight 1-Day multifocals are soft daily contact lenses. The central zone corrects distance vision while outer zones create peripheral defocus that signals slower growth. MiSight 1 Day is FDA-approved for children as young as 8. Our practice fits patients with MiSight 1 Day contact lenses as part of a structured treatment plan.
Other soft multifocal designs, including NaturalVue lenses and Biofinity monthly torics, are available at many practices. Suitability still depends on a child’s prescription and eye shape.
Low-dose atropine eye drops work differently than optical defocus. They act on receptors that influence eye growth, not on light focus. At low concentrations, side effects are minimal. Doctors report mild, temporary redness far more often than the effects linked to full-strength atropine. We offer low-dose atropine as a standalone treatment and as part of combination protocols.
Researchers writing in the journal Eye found consistent efficacy across multifocal lenses, orthokeratology, and low-dose atropine, describing atropine as a cornerstone pharmacologic therapy with consistent efficacy. Orthokeratology uses rigid gas-permeable lenses worn overnight to reshape the cornea temporarily. Many practices offer it as an alternative to daytime lens wear.
Combination Therapy and Emerging Options
For children who progress quickly on a single treatment, combining approaches is an option. Pairing low-dose atropine with peripheral defocus contact lenses or orthokeratology targets eye growth through two separate pathways at once.
A study conducted through the National Institutes of Health examined this exact pairing. It found that combining atropine with orthokeratology resulted in statistically slower axial elongation than orthokeratology alone.
Red light therapy is emerging as an option, though its trial base is still smaller than established treatments.
No single treatment works best for every child. Doctors often start with the option that fits a family’s daily routine. They adjust the plan based on how quickly the prescription changes over the following months.
Contact lens options require a child who can handle daily insertion and removal. Eye drops and glasses often fit families who prefer a simpler daily routine. Cost, comfort, and a child’s own preferences all factor into the final decision.
Parents sometimes assume that any contact lens or eye drop labeled for children is equally effective. That is not the case. Only a small number of options carry FDA approval specifically for slowing eye growth. That distinction matters when comparing choices.
Building a Myopia Management Plan That Fits Your Child
Choosing a treatment is not a one-size decision. It depends on three variables: a child’s age, current prescription, and how fast that prescription has been changing.
Progression rate matters most. A child whose prescription shifted 0.50 diopters over two years is in a different situation. Another child who shifted a full diopter in twelve months needs more active treatment.
Myopia Management Options: Lifestyle Factors vs. Clinical Treatment
Outdoor time and screen habits come up in almost every conversation about children’s vision, though their role is limited.
The AAO recommends balancing outdoor time with screen use as a preventive step alongside clinical treatment. Time outside exposes children to higher light levels, which appear to support healthy eye development. The Vision Council has also flagged screen time as a factor worth watching.
Limiting near-work time, taking regular screen breaks, and following the 20-20-20 rule are reasonable habit changes.
Outdoor time is not a treatment on its own. A separate National Institutes of Health study looked at this question directly and found that increased outdoor time alone showed limited added benefit in children already receiving clinical treatment. Vitamin D may support eye health, but it does not replace treatment in a child whose eyes are actively growing.
Monitoring Progress With Regular Eye Exams
Routine eye exams are the only way to know whether a child is progressing, stabilizing, or responding well. Doctors typically see children in active myopia management more often than once a year. A pediatric eye exam in this context is a monitoring visit. The prescription is only one data point.
We use corneal topography, axial length scans, and OCT eye imaging to track how a child’s eyes are changing. Vision therapy is another tool for patients with related coordination or focusing challenges.
Parents do not need to master every measurement themselves. The goal of a plan is simple. Catch changes early, adjust before progression speeds up, and keep the child comfortable with the chosen treatment.
Putting Together the Right Treatment Plan
Every child’s plan looks a little different. Two children with the same starting prescription may end up on different treatments. That depends on how quickly their eyes change and how well they tolerate each option.
None of this replaces a conversation with a doctor who knows a child’s history. Numbers and scans guide the plan, but they work alongside clinical judgment, not in place of it.
Whether the right approach is MiSight, Stellest, atropine, or a combination, the decision follows from the data. That data includes trials such as the peer-reviewed study confirming 75.5% (109/144) completed the clinical trial that supported MiSight’s FDA approval.
Why Waiting on Myopia Control Could Cost Your Child’s Vision
Myopia control is about more than updating a prescription each year. It addresses the underlying growth that raises the risk of complications like retinal detachment and vision loss later in life. The treatments covered here give doctors real tools to slow that growth, from contact lenses to combination therapy.
The right approach depends on a child’s age, prescription, and how quickly that prescription is changing. A conversation with an eye doctor is the clearest next step. Most families see better results by starting early. Waiting for a bigger jump in prescription rarely helps in the long run. Schedule a myopia evaluation today!
FAQs
At what age can myopia control treatment start?
Treatment can begin as early as age 6 to 8, depending on the child’s prescription and how fast it is changing. MiSight 1 Day contact lenses are FDA-approved for children as young as 8. An eye doctor will assess your child’s needs before recommending a starting point.
How do doctors measure whether a child's myopia is getting worse?
Eye doctors compare prescriptions over time and track axial length using an optical biometer. A prescription change of 0.50 diopters or more per year, or measurable axial elongation between visits, typically signals that clinical intervention is warranted beyond standard glasses or contact lenses.
Can myopia control stop nearsightedness completely?
No. Myopia control slows the rate of progression. It does not reverse existing nearsightedness or eliminate the need for corrective lenses. The goal is to reduce how much the prescription increases over time and to limit the axial elongation that raises risk for complications like retinal detachment later in life.
Are myopia control treatments safe for children?
Yes. Low-dose atropine eye drops and FDA-approved multifocal contact lenses have well-established safety profiles in pediatric clinical trials. Low-dose atropine may cause mild, temporary redness but few other side effects. An eye doctor will review a child’s health history before recommending any treatment.
Can health savings accounts or flex spending accounts be used for myopia control?
Many families use health savings accounts or flex spending accounts to cover myopia control treatment costs, since these are medically supervised programs. Eligibility depends on the specific account plan. Check with your plan administrator to confirm which treatments qualify under your coverage terms.